rethinkTHC Search
Menu
Study breakdown

Five Genetic Mutations Identified That May Explain Why Some Heavy Cannabis Users Develop Hyperemesis Syndrome

ReviewModerate evidence
The takeaway

Recent research identified five statistically significant genetic mutations distinguishing CHS patients from heavy cannabis users without symptoms, affecting the TRPV1 receptor, dopamine genes, a THC-metabolizing enzyme, and a drug transporter.

Gastroenterologists, pharmacogenomics researchers, cannabis researchers, CHS patients

5 genetic mutations distinguish CHS patients from symptom-free heavy users

What the researchers found

Five genetic mutations distinguish CHS patients from asymptomatic heavy cannabis users: mutations in TRPV1 receptor, two dopamine genes, the CYP2C9 enzyme (which metabolizes THC), and the ATP-binding cassette transporter. The syndrome is associated with escalating high-potency cannabis intake. Some patients develop classical conditioned responses to environmental triggers. The authors refute claims that pesticides, neem oil, or azadirachtin cause CHS.

Why it matters

The identification of specific genetic variants explains why CHS affects some heavy cannabis users but not others. This opens the door to genetic screening and personalized risk assessment.

The numbers in context

5 statistically significant mutations identified; affecting TRPV1, 2 dopamine genes, CYP2C9, and ABC transporter; associated with escalating high-potency cannabis use.

How the study worked

Narrative review incorporating recent genetic findings, clinical observations, and analysis of proposed alternative etiologies for CHS.

What this study cannot tell us

Narrative review format. The genetic findings require replication in larger populations. Cannot determine whether these mutations are sufficient or merely contributory.

How to read the evidence

Narrative review incorporating novel genetic findings that require replication, with thorough analysis of alternative hypotheses.

When this study was published

2024 publication

The bigger picture

Understanding CHS as a pharmacogenomic condition rather than a simple dose-response phenomenon changes how clinicians should approach diagnosis and potentially prevention. Patients with specific genetic profiles may need earlier counseling about escalating use.

Questions still open

  • Could genetic screening identify cannabis users at risk for CHS before symptoms develop?
  • Do the CYP2C9 mutations affect THC metabolism rates enough to explain symptom differences?

Common questions

Why do some heavy cannabis users get CHS while others do not?
Recent research identified 5 genetic mutations that appear to distinguish CHS patients from heavy cannabis users without symptoms. These affect how the body processes THC, dopamine signaling, and the TRPV1 pain receptor.
Is CHS caused by pesticides or contaminants?
This review specifically examines and refutes claims that CHS is caused by pesticides, neem oil, or azadirachtin, arguing that the genetic evidence points to individual susceptibility to cannabinoid effects rather than contaminant exposure.

Read the original research

Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure.

Frontiers in toxicology, 6, 1465728

Citation

Russo, Ethan B; Whiteley, Venetia L. (2024). Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure.. Frontiers in toxicology, 6, 1465728. https://doi.org/10.3389/ftox.2024.1465728

Explore the wider topic